Cardiff Park Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$546K Sell
4,536
-41
-0.9% -$4.73K 0.04% 170
2025
Q4
$482K Buy
4,577
+13
+0.3% +$1.22K 0.04% 176
2025
Q3
$383K Buy
4,564
+65
+1% +$5.35K 0.03% 210
2025
Q2
$356K Sell
4,499
-20
-0.4% -$1.59K 0.03% 205
2025
Q1
$406K Sell
4,519
-98
-2% -$9.15K 0.04% 181
2024
Q4
$459K Sell
4,617
-283
-6% -$29.2K 0.04% 165
2024
Q3
$556K Buy
4,900
+8
+0.2% +$950 0.05% 154
2024
Q2
$606K Sell
4,892
-64
-1% -$8.24K 0.06% 138
2024
Q1
$654K Sell
4,956
-64
-1% -$7.89K 0.06% 138
2023
Q4
$547K Buy
5,020
+3
+0.1% +$311 0.06% 145
2023
Q3
$516K Buy
5,017
+11
+0.2% +$1.19K 0.07% 141
2023
Q2
$578K Buy
5,006
+110
+2% +$12.5K 0.07% 134
2023
Q1
$521K Buy
4,896
+16
+0.3% +$1.73K 0.07% 134
2022
Q4
$541K Sell
4,880
-630
-11% -$64.4K 0.08% 134
2022
Q3
$475K Buy
5,510
+289
+6% +$25.8K 0.07% 143
2022
Q2
$476K Buy
5,221
+498
+11% +$44.1K 0.07% 142
2022
Q1
$388K Buy
4,723
+68
+1% +$5.36K 0.05% 168
2021
Q4
$357K Buy
+4,655
New +$371K 0.05% 173

Other funds holding MRK

Cardiff Park Advisors's MRK Position: Q1 2026 in Review

Cardiff Park Advisors reduced its Merck (MRK) stake by 0.9% in Q1 2026, selling an estimated $4.73K and leaving 4,536 shares worth $546K. The position accounts for 0.04% of the portfolio, ranked #170.

Cardiff Park Advisors first reported a position in MRK in Q4 2021 and has held it in 18 quarters since. The position peaked at $654K in Q1 2024. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Cardiff Park Advisors held 4,536 shares of Merck worth $546K as of Q1 2026.
  • Cardiff Park Advisors sold 41 Merck shares in Q1 2026, an estimated $4.73K.
  • Merck made up 0.04% of Cardiff Park Advisors's portfolio in Q1 2026, its #170 holding.
  • Cardiff Park Advisors first reported a position in Merck in Q4 2021 and has held it in 18 quarters since.
  • Cardiff Park Advisors's Merck position peaked at $654K in Q1 2024.
  • 3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Cardiff Park Advisors's 13F filing for Q1 2026, filed 15 May 2026.